SREBF1 and fatty liver disease: Furthermore, in addition to the FXR-SHP-SREBP-1c cascade, these FXR-ligand treatments significantly inhibited SREBP-1c-related lipogenesis, but did not activate PPARα-related catabolism in the mouse fatty liver model.